2026–27 flu strains set with H3N2 K; VRBPAC/FDA amid low prior VE, mRNA push; Moderna 50+ review
Key Questions
What flu strains were selected for the 2026-27 season?
WHO recommended A(H3N2) subclade K in March. VRBPAC unanimously approved on March 12-13, with FDA approval pending; trivalent vaccines shift as B/Yamagata lineage is gone.
What is new about the Moderna flu vaccine under FDA review?
FDA is reviewing Moderna's egg-free mRNA flu vaccine for ages 50+, showing 25% superior respiratory protection. This ties to low prior VE and pushes for better options.
How do 2026-27 flu updates relate to previous seasons?
Selections address low 2025-26 VE, emphasizing adjuvanted/high-dose for 65+. mRNA advancements aim for higher effectiveness amid H3N2 dominance.
WHO A(H3N2) subclade K (Mar); VRBPAC unan Mar12–13, FDA pend; FDA reviewing Moderna mRNA flu 50+ (25% sup resp, egg-free); trivalent shift B/Yamagata gone; ties to low 25-26 VE/adjuv/hd 65+ bundles.
Sources (2)
Updated Apr 8, 2026